A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer

Neoplasia

Volumn 11, Issue 6, 2009, Pages 552-563

  Yang, Ya Ting ^a,e   Balch, Curt ^b,c,d   Kulp, Samuel K ^a   Mand, Michael R ^b   Nephew, Kenneth P ^b,c   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Indiana University School of Medicine   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE 1; CYTOKERATIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; OSU HISTONE DEACETYLASE 42; PROTEIN P53; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN INTERACTION; TUMOR XENOGRAFT; UPREGULATION;

EID: 66449095669     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09204     Document Type: Article

References (68)

1. National Cancer Institute. Ovarian Cancer (Invasive) Survival Rates, By Race, Diagnosis year, Stage and Age. SEER Cancer Statistics Review 1975-2005. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/ csr/1975-2005/.
2. Ozols RF (2005). Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 (Suppl 1), 3-11. (Pubitemid 40696471)
3. Orkin SH, Harosi FI, and Leder P (1975). Differentiation in erythroleukemic cells and their somatic hybrids. Proc Natl Acad Sci USA 72, 98-102.
4. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, and Marks PA (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95, 3003-3007. (Pubitemid 28135844)
5. Bolden JE, Peart MJ, and Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5, 769-784. (Pubitemid 44348499)
6. Minucci S and Pelicci PG (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51. (Pubitemid 43054973)
7. Marks PA and Breslow R (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25, 84-90. (Pubitemid 46087907)
8. Garber K (2007). HDAC inhibitors overcome first hurdle. Nat Biotechnol 25, 17-19. (Pubitemid 46087886)
9. Lee MJ, Kim YS, Kummar S, Giaccone G, and Trepel JB (2008). Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20, 639-649.
10. Marsoni S, Damia G, and Camboni G (2008). A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 3, 164-171.
11. Modesitt SC, Sill M, Hoffman JS, and Bender DP (2008). A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109, 182-186.
12. Wang DF, Helquist P, Wiech NL, and Wiest O (2005). Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 48, 6936-6947. (Pubitemid 41533115)
13. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, and Pavletich NP (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193. (Pubitemid 29436325)
14. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, and Marks PA (1996). Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93, 5705-5708. (Pubitemid 26191313)
15. Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C, and Loidl P (1999). Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem 42, 4669-4679. (Pubitemid 29530020)
16. Marks PA (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26, 1351-1356. (Pubitemid 46328465)
17. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, and Shimomura K (1994). FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 47, 315-323.
18. Lu Q, Wang DS, Chen CS, Hu YD, and Chen CS (2005). Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 48, 5530-5535. (Pubitemid 41209250)
19. Kulp SK, Chen CS, Wang DS, Chen CY, and Chen CS (2006). Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S )-HDAC-42, in prostate cancer. Clin Cancer Res 12, 5199-5206. (Pubitemid 44453349)
20. Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, and Chen CS (2008). OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 68, 3999-4009.
21. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, et al. (2007). Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46, 1119-1130. (Pubitemid 350144776)
22. Chen CS, Weng SC, Tseng PH, and Lin HP (2005). Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280, 38879-38887. (Pubitemid 43853791)
23. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, and Chen CS (2007). Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67, 5318-5327. (Pubitemid 46997271)
24. Townsend DM, Shen H, Staros AL, Gate L, and Tew KD (2002). Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther 1, 1089-1095.
25. Shao CJ, Fu J, Shi HL, Mu YG, and Chen ZP (2008). Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol 89, 27-35.
26. Cannistra SA (2004). Cancer of the ovary. N Engl J Med 351, 2519-2529.
27. Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, Cheng AS, Yan PS, Davuluri RV, Huang TH, et al. (2008). Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 10, 908-919.
28. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, and Kobel M (2008). Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10, 1021-1027.
29. Vanhaecke T, Papeleu P, Elaut G, and Rogiers V (2004). Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 11, 1629-1643. (Pubitemid 38735799)
30. Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH, and Nephew KP (2001). DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 82, 261-268.
31. Kruk PA, Maines-Bandiera SL, and Auersperg N (1990). A simplified method to culture human ovarian surface epithelium. Lab Invest 63, 132-136. (Pubitemid 20234682)
32. Chou TC (1976). Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59, 253-276.
33. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408. (Pubitemid 34164012)
34. Goddard MJ, Wilson B, and Grant JW (1991). Comparison of commercially available cytokeratin antibodies in normal and neoplastic adult epithelial and non-epithelial tissues. J Clin Pathol 44, 660-663.
35. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, and Richon VM (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60, 5165-5170.
36. Clarke PA, Pestell KE, Di Stefano F, Workman P, and Walton MI (2004). Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo. Br J Cancer 91, 1614-1623. (Pubitemid 39486371)
37. Buchler P, Reber HA, Lavey RS, Tomlinson J, Buchler MW, Friess H, and Hines OJ (2004). Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res 120, 295-303. (Pubitemid 38834199)
38. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, and Ozols RF (1987). Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47, 414-418. (Pubitemid 17009602)
39. Johnson SW, Laub PB, Beesley JS, Ozols RF, and Hamilton TC (1997). Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57, 850-856. (Pubitemid 27098008)
40. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, and Johnson SW (2005). Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92, 1149-1158. (Pubitemid 40546683)
41. Porter LA and Donoghue DJ (2003). Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res 5, 335-347.
42. Yu J and Zhang L (2005). The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331, 851-858. (Pubitemid 40615516)
43. Kouzarides T (2000). Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19, 1176-1179.
44. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, and Bates SE (2002). Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1, 937-941.
45. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3-26.
46. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, and Ford CD (2002). Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1, 1181-1190.
47. Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH, and Ilstrup SJ (2005). Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther 4, 603-611. (Pubitemid 40601842)
48. Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7, 573-584.
49. Dean M, Fojo T, and Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284. (Pubitemid 40488633)
50. Vermes I, Haanen C, Steffens-Nakken H, and Reutelingsperger C (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184, 39-51.
51. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, and Koeffler HP (2004). Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101, 2760-2770. (Pubitemid 39603184)
52. Kuendgen A and Gattermann N (2007). Valproic acid for the treatment of myeloid malignancies. Cancer 110, 943-954. (Pubitemid 47312858)
53. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, and Brown R (2003). Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2, 721-728.
54. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, and Jeffers M (2006). Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5, 2086-2095. (Pubitemid 44336581)
55. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, and Yu MH (2008). Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 99, 1218-1226.
56. Takai N, Ueda T, Nishida M, Nasu K, and Narahara H (2006). M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol Oncol 101, 108-113. (Pubitemid 43303568)
57. Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, and Wan Y (2006). Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 29, 269-278.
58. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, and Kohno M (2008). Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 99, 376-384.
59. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, and Gabrielli BG (2000). Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11, 2069-2083. (Pubitemid 30408065)
60. Archer SY, Johnson J, Kim HJ, Ma Q, Mou H, Daesety V, Meng S, and Hodin RA (2005). The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol 289, G696-G703. (Pubitemid 41377176)
61. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, and Fojo T (2005). Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 65, 7386-7392. (Pubitemid 41161272)
62. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, and Shin DY (1999). p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 274, 29677-29682. (Pubitemid 29483335)
63. Liu N, Lucibello FC, Korner K, Wolfraim LA, Zwicker J, and Muller R (1997). CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Nucleic Acids Res 25, 4915-4920. (Pubitemid 28022250)
64. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET, and Gannon F (2005). Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24, 4894-4907. (Pubitemid 41129094)
65. Biade S, Stobbe CC, and Chapman JD (1997). The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res 147, 416-421. (Pubitemid 27150371)
66. Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A, and Tuosto L (2008). Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther 7, 1410-1419.
67. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, and Schreiber SL (2003). Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100, 4389-4394. (Pubitemid 36457739)
68. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, and Yao TP (2008). The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68, 7561-7569.